Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
| Errataetall: |
CommentOn: Med Clin (Engl Ed). 2022 Apr 8;158(7):301-307. - PMID 35531306 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:159 |
|---|---|
| Enthalten in: |
Medicina clinica - 159(2022), 8 vom: 28. Okt., Seite e54 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Efecto del tocilizumab frente a cuidado estándar en pacientes adultos hospitalizados con neumonía por COVID-19 moderada-grave |
|---|
| Beteiligte Personen: |
Aomar-Millán, Ismael F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 18.10.2022 Date Revised 17.12.2022 published: Print-Electronic CommentOn: Med Clin (Engl Ed). 2022 Apr 8;158(7):301-307. - PMID 35531306 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medcli.2022.04.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34581679X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34581679X | ||
| 003 | DE-627 | ||
| 005 | 20231226025933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medcli.2022.04.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1152.xml |
| 035 | |a (DE-627)NLM34581679X | ||
| 035 | |a (NLM)36064504 | ||
| 035 | |a (PII)S0025-7753(22)00358-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aomar-Millán, Ismael F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia |
| 246 | 3 | 3 | |a Efecto del tocilizumab frente a cuidado estándar en pacientes adultos hospitalizados con neumonía por COVID-19 moderada-grave |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2022 | ||
| 500 | |a Date Revised 17.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Med Clin (Engl Ed). 2022 Apr 8;158(7):301-307. - PMID 35531306 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Salvatierra, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Raya Álvarez, Enrique |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica |d 1948 |g 159(2022), 8 vom: 28. Okt., Seite e54 |w (DE-627)NLM000359017 |x 1578-8989 |7 nnns |
| 773 | 1 | 8 | |g volume:159 |g year:2022 |g number:8 |g day:28 |g month:10 |g pages:e54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medcli.2022.04.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 159 |j 2022 |e 8 |b 28 |c 10 |h e54 | ||